An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
Join the Moores Cancer Center (MCC), Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
Terrance Mayes, Loretta Erhunmwunsee Named Leaders of NCCN Forum on Equity
Read full article on page 16 of The Cancer Letter, volume 49 number 3.
Pancreatic Cancer Survival Edges Up—As Screening Strategies Emerge
Read full article on page 31 of The Cancer Letter, volume 49 number 3.
|
|
|
|
Pharmacology Seminar Series
Inner Workings of the Inflammasome Engine
Tuesday, January 24, 2023 (IN PERSON) at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
9500 Gilman Drive, La Jolla, CA 92037
Optional Webinar Registration
Hao Wu, Ph.D.
Asa and Patricia Springer Professor
Department of Biological Chemistry and Molecular Pharmacology
Harvard Medical School and Boston Children's Hospital
Hosted by Susan Taylor, Ph.D.
|
|
|
Cancer Genomics Cross-Laboratory Meeting
Pathways Suppressing Genomic Instability
Wednesday, January 25, 2023 at 12:00 p.m. PT
Christopher Putnam, Ph.D.
Associate Investigator, Ludwig Institute for Cancer Research
Associate Professor, UC San Diego, School of Medicine
Contact: V4hernandez@health.ucsd.edu
|
|
|
| DRM Seminar Series
APOBEC3 Enzymes: From Retroviral Restriction Factors to Cancer Drivers . . . and Beyond?
Wednesday, January 25, 2023 from 3:00 to 4:00 p.m. PT
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
Zoom Link Available Upon Request
Tim Fenton, Ph.D.
Associate Professor, Cancer Biology
Faculty of Medicine
School of Cancer Sciences/Centre for Cancer Immunology
University of Southampton
Hosted by Frank Furnari, Ph.D.
Contact: drmseminarseries@ucsd.edu
|
|
|
|
Pharmacology Seminar Series
The LKB1-AMPK Pathway: Central Cell Metabolism and Tumor Suppressor Function
Tuesday, January 31, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
9500 Gilman Drive, La Jolla, CA 92037
Optional Webinar Registration
Reuben J. Shaw, Ph.D.
Professor, Molecular and Cell Biology
Laboratory Director, Salk NCI-Designated Cancer Center
The Salk Institute for Biological Studies
Hosted by Susan Taylor, Ph.D.
Contact: pharmeducation@health.ucsd.edu
|
|
|
|
Cancer Control Program Work In Progress Seminar Series
Integrating “When to Eat” and “Who Should Eat” and Concepts to Evaluate Inflammatory Foods
Wednesday, February 1, 2023 at 12:00 p.m. PT
MCC Comor Commons Conference Room
Lunch provided, beginning at 11:30 a.m.
Optional Webinar Registration
Tianying Wu, Ph.D.
Associate Professor
San Diego State University, School of Public Health
Division of Epidemiology and Biostatistics
|
|
|
|
Pharmacology Seminar Series
Co-organized by the Institute for Diabetes and Metabolic Health and the Cancer Therapeutics (CT2) Training Program
Targeting the Liver Mitochondria to Treat NAFLD/NASH and Cardiometabolic Disease
Monday, February 6, 2023 at 11:00 a.m. PT
Leichtag Biomedical Research Building, Room 107
9500 Gilman Drive, La Jolla, CA 92037
Optional Webinar Registration
Gerald Shulman M.D., Ph.D., MACP, MACE, FRCP
Professor, Molecular and Cell Biology Laboratory
George R. Cowgill Professor of Medicine (Endocrinology) and Professor of Cellular And Molecular Physiology
Co-Director Yale Diabetes Research Center, Internal Medicine
Yale School of Medicine
Hosted by Alan Saltiel, Ph.D., J. Silvio Gutkind, Ph.D., and Dwayne Stupack, Ph.D.
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
San Diego Colorectal Cancer Screening Roundtable
Thursday, February 22, 2023 from 10:00 a.m. to 12:00 p.m.
Join us for information on the current state of colorectal cancer screening in San Diego, upcoming changes in Medi-Cal, emerging screening tests, and how we can increase screening to get back on track.
This roundtable is designed for medical directors, clinicians, quality improvement staff, panel managers, project managers, and health center staff to hear and share best practices on improving colorectal cancer screenings in San Diego County.
|
| |
MCC Speed Mentoring Workshop
Thursday, February 9, 2023 at 12:00 p.m. via Zoom
Students, postdocs, and junior faculty are welcome. This virtual workshop lasts for one hour, and each trainee (undergraduate, graduate student, medical student, postdoc, resident, fellow, and junior faculty) will have the opportunity to speak with all three mentors. It is a great way to get advice from a variety of perspectives in a short amount of time!
Details and Zoom link will be emailed once registration is completed.
Organized by the MCC Cancer Research Training & Education Coordination (CRTEC) Program
For more information or to sign-up for our monthly Speed Mentor Workshop listserv, please contact Diana Arroyo at d1arroyo@ucsd.edu
|
|
|
Student Volunteers Available
MCC CRTEC has identified three motivated undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab. Please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu, if you would like to connect with one or more of these students:
|
- Third-year UCSD undergraduate majoring in Biology, minoring in Math
- Second-year UCSD premed undergraduate majoring in Human Biology
-
First-year UCSD undergraduate majoring in Cognitive and Behavioral Neuroscience
|
CRTEC administration will complete all necessary paperwork for these student volunteers.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC CRTEC. These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Faculty Seed Grant Proposals for 2023-2024 Award Year
Maximum funding $75,000 for 2023-2024
The University of California (UC) Cancer Research Coordinating Committee (CRCC) is a systemwide, faculty-directed cancer research program that provides competitive intramural research awards for topics in any discipline that address any aspect of cancer, which include its origins, detection, prevention, and cure. The UC CRCC provides 1-year seed grants to faculty on the 10 UC campuses, with the expectation that the most promising endeavors will become competitive for larger, long-term grants from other funding sources. Awards are made in two categories: New Assistant Professor (NAP) and Regular (REG).
Required LOI Deadline: January 24, 2023
Application Deadline: April 13, 2023
|
| |
Advancing Head and Neck Cancer Early Detection (AHEAD) Research
Maximum funding $500,000 direct costs/year for 5 years
The purpose of this funding opportunity announcement (FOA) is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This FOA seeks applications that target early detection of HNC by (1) applying molecular, cellular, and multi-omics signatures to clinical studies for differentiating benign from premalignant lesions and (2) identifying prognostic signatures on the transformation from premalignant to malignant lesions.
Deadline: January 27, 2023 at 5:00 p.m.
|
|
|
The UC Pancreatic Cancer Consortium Plans to Submit a SPORE Proposal to the National Cancer Institute (NCI) in May, 2023
As you may know, SPORE project proposals are distinctly different from either R01 or U01 research mechanisms, in that the proposed projects must be translational. In every SPORE project, the development of new cancer-relevant interventions should include both a laboratory component and a human application (see RFP linked below for further detail). Project budgets are expected on the order of $200,000–$250,000/year for 5 years, although projects on early detection, prevention, or population science can request up to an additional $120,000/year.
Deadline: Tuesday, January 31, 2023
Questions? Contact Kurt Giles, D.Phil. at kurt.giles@ucsf.edu
|
|
|
Prostate Cancer Foundation (PCF) 2023 Young Investigator Awards Request for Letters of Intent/Full Applications
Award: $75,000 per year for 3 years
The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. For example, this includes funding "protected time" or direct costs for laboratory science. This award does not support indirect costs, such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of one to three mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.
LOI Deadline: February 10, 2023 by 3:00 p.m. ET
Submission Portal Opens: Monday, February 27, 2023
Invited Full Application Deadline: Monday, April 24, 2023 by 3:00 p.m. ET
Questions? Contact LettersofIntent@pcf.org.
|
|
|
Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
Application budgets may not exceed $500,000 in direct costs per year for the UG3 phase and may not exceed $750,000 in direct costs per year for the UH3 phase
Through this FOA, the NCI intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Deadline: February 14, 2023 by 5:00 p.m. and June 14, 2023 by 5:00 p.m.
|
|
|
2023 ACTRI Pilot Projects: Community Research Partnership
These UCSD, Altman Clinical and Translational Research Institute (ACTRI) grants are (1) 1-year competitive awards (up to $30,000) to provide funding for early-stage projects and (2) available to all ACTRI members with faculty appointments; funding priority is given to early-career faculty.
Requests for assistance with identifying potential community or academic partners should be made between October 2022 and November 2022.
Deadline: Friday, February 24, 2023 by 2:00 p.m. PT
|
|
|
University of California, Hematologic Malignancies Consortium (UCHMC) Request for Proposals (RFP)
The UCHMC is requesting submission of proposals within two potential areas of funding: RFP A and RFP B.
All applications are to be submitted via email as a single PDF to Jesika Reiner, M.P.H., M.B.A. at JReiner@uchmc.org and Mwieduwilt@uchmc.org.
RFP A: UCHMC Funds for Junior Faculty and Trainee Competitive Seed Grants
This funding will support single or multi-center pilot clinical trials, translational lab-based projects, or retrospective projects, which may ultimately grow into multi-center UCHMC interventional clinical trials. Funding may be applied for fellowship support to conduct clinical trials research with the UCHMC. Funding also may support correlative research that may or may not be associated with an existing UCHMC trial yet with translational aims that possess potential for development into a UCHMC trial. The award amount will be determined by the UCHMC Steering Committee, but individual requests should not exceed $40,000.
RFP B: UCHMC Funds for Clinical Trials Support
This funding will support underfunded yet promising clinical trials and correlative research projects associated with an existing clinical trials or other multi-center projects that hold promise for development into larger multicenter UCHMC clinical trials. These awards will range from $100,000 to $150,000 in a given award period, with the number of projects awarded based on number of applications and scientific need as determined by the UCHMC Steering Committee, which reserves the right to award a larger total funds as it see fit.
Applicants may apply for both RFPs but will be awarded only one as a lead investigator. An applicant can be a collaborator on more than one application in a given award period.
Application Format
|
- Cover Page
- Project title
- Project investigators (Lead and Sub-Investigators) and affiliations
- Project start date
- Project end date
- Concurrent UCHMC applications of Lead Investigator
- Applicant contact
- Project Information
- Brief project description with hypothesis(es)
- Detailed project description with supporting preclinical and/or clinical data, rationale, study design, and statistical plan, as appropriate
- Budget
- Budget justification
- Other sources of funding
-
Statement of commitment to develop results into UCHMC interventional clinical trials when possible
- Attachments
- CVs of investigators associated with the proposed project
|
|
|
Call for Applications to Fund Travel to Scholarly Meeting for FY 2022/23, Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
Applications may be submitted throughout the year but must be received and approved prior to the conference start date. Applications will be reviewed while funds are available. Funds will not be awarded retroactively.
Any UCSD Health Sciences (HS) Clinical series faculty member holding an M.D. or D.O. can receive one trip every other fiscal year (July 1-June 30). Travel awards (domestic or foreign) will be made for a maximum of $750 toward standard economy airfare and/or registration fees (documentation required).
Eligibility is to HS Clinical series faculty who (1) have an accepted abstract to a scientific professional society conference, (2) are not a member of the Academic Senate, and (3) are either the first or senior author on the abstract podium or poster presentation of original clinical research. Invited lectures, workshops, or panel or moderator invites are ineligible and will not be considered.
|
|
|
Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
R01 Award: Maximum duration is 5 years. For over $500,000/year in direct costs, NIH approval is required.
R21 Award: Combined budget for direct costs for the 2-year maximum project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
NCI Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
Award: Application budgets are not limited yet must reflect the actual needs of the proposed project. The project period may not exceed 5 years.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Notice of Special Interest (NOSI): Administrative Supplement to Support Global Cancer Stigma Research
This Notice of Special Interest (NOSI) informs current awardees that the NCI is providing an opportunity for supplemental funding to support exploratory research studies to expand the current understanding of cancer stigma (as defined below), assess its impact on cancer control and prevention, and develop stigma-reduction interventions to improve cancer outcomes in low- and middle-income countries (LMICs).
Applications can be submitted on a rolling basis between January 16, 2023 - May 21, 2023, at 5:00 PM local time of applicant organization for FY 2023 funding. Applications for this initiative must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
|
|
NCI Cancer Screening Research Network: Coordinating and Communication Center (CCC) (UG1 Clinical Trial Required)
NCI intends to commit $1.5M in FY 2024 to fund one award; $2M is expected to be allocated per year in subsequent years for the CCC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
|
|
NCI Cancer Screening Research Network: Statistics and Data Management Center (SDMC) (UG1 Clinical Trial Required)
NCI intends to commit $1M in FY 2024 to fund one award; $2M is expected to be allocated to per year in subsequent years for the SDMC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
|
|
NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1 Clinical Trial Required)
NCI intends to commit $8M in FY 2024 to fund 10-15 awards. $9M is expected to be allocated per year in subsequent years for ACCESS Hub; requested budget must not exceed $750,000 in direct costs per year; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
| Damon Runyon, Clinical Investigator Award
Award: $600,000 award for 3 years, distributed as $200,000 per year.
Deadline: February 1, 2023 at 4:00 p.m. ET
|
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Maximum budget $375,000 direct costs/year for 5 years; NIH R01 standard due dates apply.
Deadline: February 5, 2023 at 5:00 p.m.
|
|
|
Coordinating Center for Cannabis and Cannabinoid Use Among Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 17, 2023 at 5:00 p.m. PT
|
|
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 18, 2023 at 5:00 p.m. PT
|
|
Notice of Special Interest (NOSI): Administrative Supplement for NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
One CAP-IT Data and Resource Coordination Center will be awarded with a maximum total cost of $800,000 per year (maximum direct cost is $480,000 per year) in fiscal year 2023; at least 1 full year on the parent grant must remain at the time of funding; application budget is limited to 4 years.
Deadline: February 28, 2023
|
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, U2C Clinical Trial Optional)
Application budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
| NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
A budget for direct costs of up to $50,000 per year may be requested; maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
|
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
The combined budget for direct costs for the 2-year maximum project period may not exceed $275,000; no more than $200,000 may be requested in any single year.
Deadline: Standard NIH deadlines apply
|
|
|
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Application budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are limited to $600,000 direct costs (excluding consortium F&A) per year; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| Notice of Special Interest (NOSI): Adaptive Biomaterials for Cancer Biology
This NOSI invites applications that propose the development of advanced biomaterials for use in fundamental cancer biology research and proposals incorporating the novel application of advanced biomaterials to address cancer biology research questions.
Deadline: Standard NIH deadlines apply
|
|
|
Saturday, January 28, 2023
|
|
|
Living with Melanoma Patient Symposium
Saturday, February 4, 2023 from 8:30 a.m. to 12:00 p.m.
University of California, San Francisco, Mission Bay Campus
Arthur and Toni Rembe Rock Hall
1550 4th Street, San Francisco, CA 94158
Hosted by the AIM at Melanoma Foundation and the University of California (UC) Melanoma & Skin Cancer Consortium, this symposium will bring together five of the UC's National Cancer Institute-designated Comprehensive Cancer Centers to share research, clinical trials, and best practices.
|
|
|
Salk T32 Cancer Symposium
Friday, February 10, 2023 from 8:30 a.m. to 5:00 p.m.
Salk Institute, Conrad T. Prebys Auditorium
10010 North Torrey Pines Road
La Jolla, CA 92037
The theme of this year’s symposium is cancer therapeutics. An outstanding lineup of speakers will present on topics that include precision medicine, cancer epigenetics, and immunotherapy. The goal of the symposium is to highlight the amazing research being done by postdocs and students. Those working in cancer biology are encouraged to join attend (deadline: January 27, 2023) and to submit an abstract (deadline: January 9, 2023).
|
|
|
Kyoto University Symposium
Tuesday, February 28, 2023 from 1:00 p.m. to 5:00 p.m.
Roth Auditorium
Sanford Consortium for Regenerative Medicine
|
|
|
| Keynote Speaker
Dr. Shinya Yamanaka
Nobel Laureate in Physiology or Medicine 2012
Director Emeritus and Professor
Department of Life Science Frontiers
Center for iPS Cell Research and Application
Kyoto University
Read More
|
|
|
The symposium will be followed by a reception at the Bella Vista Cafe. Save the date and join us for this unique opportunity to reinvigorate academic collaborations with the prestigious university in Japan.
For more information, please contact Ms. Mariko Adachi, International Strategy Office, Kyoto University at osl.symposium@mail2.adm.kyoto-u.ac.jp
|
|
|
Solid Tumor Therapeutics Program Retreat
Friday, March 3, 2023 from 9:00 a.m. to 4:30 p.m.
UCSD MCC Goldberg Auditorium
The retreat will include catered breakfast and lunch.
|
|
|
Luis Diaz, M.D.
Grayer Family Chair Head, Division of Solid Tumor Oncology Professor, Weill Cornell Medical School
|
|
Lisa Butterfield, Ph.D.
Adjunct Professor of Microbiology and Immunology
University of California, San Francisco
|
|
|
Additional Speakers Include
Sonia Sharma, Ph.D. Anandra W. Goldrath, Ph.D. Liangfang Zhang, Ph.D. Nicole Steinmetz, Ph.D. Shweta Joshi, Ph.D. Tariq Rana, Ph.D. Rebekah White, M.D., FACS Rebecca Shatsky, M.D.
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
| Congratulations to Molly Klipfel for Being Recognized as Clinical Trials Office (CTO), Staff of the Month for the Month of December, 2022!
The CTO and Breast Team are recognizing Molly for being reliable, professional, dedicated, and kind. She is a team player and always approaches challenges with a positive attitude. Leading up to the FDA Audit for the Breast Team, Molly put in countless hours, preparing the charts and reviewing every detail. She showed excellent leadership skills through thoughtful delegation and creative problem solving. During the audit, she remained calm in a very stressful situation and put everyone in the room at ease. Molly is a good communicator, both with her team and her patients, and is always eager to learn something new. The Breast Team is lucky to have such an excellent coordinator! Kudos to Molly!
|
|
|
SHARED RESOURCE SPOTLIGHT
|
|
|
New Community Outreach Partnership with El Centro Regional Medical Center (ECRMC)
On December 15, 2022, the El Centro Regional Medical Center (ECRMC) Multidisciplinary Research Council (MRC) approved a collaborative project with the MCC Biorepository and Tissue Technology Shared Resource (BTTSR), a College of American Pathologists (CAP)-accredited core. This project will support biospecimen procurement at ECRMC, with the main purpose of bridging the gap in the participation in research by populations with health disparities.
For more details, please contact BTTSR at skaushal@health.ucsd.edu
|
|
|
Biostatistics Shared Resource (BSR)
The MCC BSR not only provides comprehensive biostatistics and data analytics collaboration and support, but also is happy to help with grant and protocol development.
The BSR, established in 1995, currently comprises six faculty members and two staff biostatisticians. Together, BSR faculty and staff support best practices in data analysis and statistical inference; reproducible research; clinical trial design, reporting and analysis; causal inference from observational studies; and statistical methodology.
MCC members are not charged for BSR consulting during proposal preparation and early clinical trial protocol development. The BSR's MCC funding is intended for development of long-term collaboration that leads to not only foundation, federal, and industry funding, but also high-profile publications. The BSR also welcomes short consultation requests. Funded projects are expected to incorporate a budget for adequate biostatistics support, which often strengthens grant applications.
The BSR encourages early interaction during proposal planning. For standard proposal development, the BSR needs 4 weeks' advanced notice to review aims, methods, and preliminary results. The BSR can provide not only statistical sections, which include sample size, power calculations, and analysis methods, but also targeted biosketches and letters of support for grant proposals. The BSR recommends contacting the BSR Manager at least 8 weeks in advance for more complex multi-PI, multi-institution, multi-project proposals.
Early interaction during clinical trial development is encouraged. The BSR will provide not only sample size, power calculations, and justifications for any interim safety and/or efficacy analysis, but also randomization plans. During trial operation, the BSR can provide DSMB and regulatory reports, in addition to interim safety and/or final efficacy analysis. The BSR requires negotiated approval of trial budget prior to undertaking these activities.
Please feel free to contact the BSR, which aims to respond within 2 days with a consultation plan. Email Emily Pittman, Ph.D., BSR Manager at eipittman@health.ucsd.edu.
|
|
|
-
Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR (STT), Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023 JAN 01.
- Luo W, Adamska JZ, Li C, Verma R, Liu Q, Hagan T, Wimmers F, Gupta S, Feng Y, Jiang W, Zhou J, Valore E, Wang Y, Trisal M, Subramaniam S (SFG), Osborne TF, Pulendran B. SREBP signaling is essential for effective B cell responses. Nat Immunol. 2022 DEC 28.
-
Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, Lee JH, Lee JI, Kweon YO, Weltman M, Harrison SA, Neuschwander-Tetri BA, Cusi K, Loomba R (CCP), Given BD, Christianson DR, Garcia-Medel E, Yi M, Hamilton J, Yuen MF. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. J Hepatol. 2022 DEC 10.
- Pulsipher MA, Ahn KW, Bunin NJ, Lalefar N, Anderson EJ (ZY), Flower A, Cairo MS, Talano JA, Chaudhury S, Kitko CL, Duke JL, Monos D, Leung W, Dvorak CC, Abdel-Azim H. KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial. Blood. 2022 DEC 15.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to this newsletter, please make use of the newsletter submission form that is linked below.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the MCC weekly newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the MCC website. Please provide us with the data that we need to showcase your great work by completing the Member Survey linked below.
We sincerely thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and cancer-risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. Holding Comprehensive status since 2001, MCC was founded in 1977 by John Mendelsohn and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to schristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|